Table 3.
Comparison of the Frequency, Clinical Symptoms, and Antibiotic Resistance of DEC and E. coli Pathotypes in This Study and in Other Studies
| E. coli Pathotypes | Shiraz (Iran) | India | China (Throughout the Country) | Tehran (Iran) | Sudan | Iran’s North and Northwest Provinces | China (Southeastern) | |
|---|---|---|---|---|---|---|---|---|
| DEC | 43.6% | 30.7% | 5% | 58.9% | 48% | 27% | 14.1% | |
| EAEC | 23.6% | 6.9% | 1.6% | 16.6% | 43% | 0% | 62.5% | |
| EPEC | 10.9% | 21.5% | 1.6% | 12.6% | 29% | 10.5% | 15% | |
| ETEC | 3.6% | 10.7% | 1% | 10.8% | 18% | 5.8% | 17.9% | |
| EIEC | 5.5% | – | 0.5% | – | 9% | 0% | 0.3% | |
| EHEC | 0% | 4.6% | 0.3% | 18.9% | – | 3.5% | 4% | |
| The most abundant E. coli pathotype | EAEC 84.6% | EPEC 21.5% | EAEC and EPEC 1.6% | EHEC 18.9% | EAEC 43% | EPEC 10.5% | EAEC 62.5% | |
| Clinical symptoms in patients with DEC | Mucus in the stool | – | – | 65% | 51.5% | – | – | – |
| Abdominal pain | – | – | 3.4% | – | – | – | – | |
| Vomiting | – | – | 5.1% | 52.6% | – | – | – | |
| Antibiotic resistance in patients with DEC | Nalidixic acid | – | – | – | – | 34% | – | – |
| Ampicillin | 93.8% | – | – | – | 47% | – | 91.8% | |
| Tetracycline | – | – | – | – | 24% | – | 57% | |
| Cotrimoxazole | 77.1% | – | – | – | – | – | 52.3% | |
| Cefotaxime | 66.7% | – | – | – | – | – | 35.7% | |
| Ceftriaxone | 66.7% | – | – | – | – | – | – | |
| ESBL in DEC isolates | 66.7% | – | – | – | – | – | 34.5% | |
| The most abundant ESBL genes | – | – | – | – | – | – | blaCTX-M 94.2% | |
| References | 16 | 14 | 27 | 11 | 28 | 29 | 30 | |
Note: Not reviewed.